Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Upgraded by Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

Several other equities research analysts have also commented on the stock. Piper Sandler lowered shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. Raymond James Financial downgraded shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Barclays set a $5.00 price target on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a research report on Monday, October 13th. Finally, Cantor Fitzgerald downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $55.50.

Tvardi Therapeutics Price Performance

TVRD opened at $4.03 on Tuesday. Tvardi Therapeutics has a 1-year low of $3.74 and a 1-year high of $43.65. The stock has a market cap of $37.80 million, a P/E ratio of -0.42 and a beta of 0.09. The stock’s 50 day simple moving average is $4.16 and its 200 day simple moving average is $18.65.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its earnings results on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24.

Hedge Funds Weigh In On Tvardi Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics during the second quarter worth approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics in the 2nd quarter valued at $43,000. Headlands Technologies LLC purchased a new position in shares of Tvardi Therapeutics during the 2nd quarter worth $80,000. New York State Common Retirement Fund acquired a new stake in shares of Tvardi Therapeutics during the second quarter worth $92,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Tvardi Therapeutics during the third quarter worth $318,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.